Clinical trial
Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck…
NCT00281866 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Completed
Key facts
| NCT number | NCT00281866 |
|---|---|
| Title | Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer |
| Official title | Genotypic-Based Pharmacodynamic Evaluation of Erlotinib (Erlotinib (Tarceva™, OSI Pharmaceuticals, Uniondale, NY) in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | erlotinib hydrochloride |
| Enrollment | 37 |
| Start date | Jul 1, 2005 |
| Primary completion | Oct 1, 2006 |
| Completion | Mar 1, 2007 |
| First posted | Jan 25, 2006 |
| Last update posted | Oct 12, 2016 |
| Countries | Spain, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: